First-pass extracted concept

adeno-associated virus vectors

Candidate: concept label3 source documents5 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

AAV, AAV vectors

Evidence Snippets

This review focuses on current in vivo CAR-T delivery strategies, including viral vectors (such as lentiviruses, γ-retroviruses, adeno-associated viruses, and viral-like particles)...

Evidence 1Source 1DOI PubMedprovenance

Since 2021, the U.S. Food and Drug Administration (FDA) has approved seven new viral vector-based gene therapies, five of which use adeno-associated virus (AAV) vectors, reinforcing their status as the leading platform for in vivo gene delivery.

Evidence 2Source 2DOI PubMedprovenance

Twenty macaque monkeys were evaluated after being injected with adeno-associated virus vectors expressing the DREADDs hM4Di or hM3Dq

Evidence 3Source 3DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 1 linked claim Claim 1

Source 2primary paper2026MEDDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Source 3primary paper2025MEDDOI PubMed

1 evidence snippet 0 linked claims

Linked Claims

Claim 1clinical landscape summarysupports2026Source 2DOI PubMed

Since 2021, the FDA has approved seven new viral vector-based gene therapies.

Claim 2design objectivesupports2026Source 1DOI PubMed

Current in vivo CAR-T delivery platforms are engineered to achieve efficient, specific, and safe CAR transgene transfer.

Claim 3engineering trendsupports2026Source 2DOI PubMed

Disease-specific patterns of capsid usage indicate advancement in tailored capsid engineering based on anatomical targeting needs.

Claim 4field maturationsupports2026Source 2DOI PubMed

Viral vector technologies are maturing from proof-of-concept studies toward precision platforms capable of addressing rare monogenic disorders and more prevalent complex diseases.

Claim 5platform prevalencesupports2026Source 2DOI PubMed

Five of the seven newly approved viral vector-based gene therapies since 2021 use AAV vectors, supporting AAV as the leading platform for in vivo gene delivery.